Stocktoria
BIOGEN INC. BIIB
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1991-09-17
BIOGEN INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $9.9B | $9.7B | $9.8B | $10.2B | $11.0B |
| SG&A expense | $2.4B | $2.4B | $2.5B | $2.4B | $2.7B |
| Operating income | — | — | — | — | $2.8B |
| Interest expense | $267.5M | $250.3M | $246.9M | $246.6M | $253.6M |
| Income tax | $263.6M | $273.8M | $135.3M | $632.8M | $52.5M |
| Net income | $1.3B | $1.6B | $1.2B | $3.0B | $1.6B |
| EPS (diluted) | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 |
| Operating cash flow | $2.2B | $2.9B | $1.5B | $1.4B | $3.6B |
| Free cash flow | $2.1B | $2.7B | $1.3B | $1.1B | $3.4B |
| Inventory | $2.2B | $2.5B | $2.5B | $1.3B | $1.4B |
| Total assets | $29.4B | $28.0B | $26.8B | $24.6B | $23.9B |
| Total liabilities | $11.2B | $11.3B | $12.0B | $11.2B | $12.9B |
| Shareholders' equity | $18.3B | $16.7B | $14.8B | $13.4B | $11.0B |
Source: SEC EDGAR filings · CIK 0000875045 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.